NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary fibrosis (IPF). Under this strategic research collaboration, the company will work with teams of two leading experts in interstitial lung disease: Naftali Kaminski, MD, a…
A man with idiopathic pulmonary fibrosis (IPF) was kept alive and his blood oxygenated for more than a year while waiting for a lung transplant using a type of extracorporeal membrane oxygenation (ECMO) called veno-venous ECMO — a procedure usually limited in use to about two weeks, researchers in Japan report. They estimate that one…
Astragaloside IV — a compound isolated from a traditional Chinese medicinal plant — was found to reverse epithelial–mesenchymal transition, a process crucial to the progression of fibrosis, through its impact on a protein called FOXO3a, a study by researchers in China reports. The study, “Astragaloside IV modulates TGF-b1-dependent epithelial-mesenchymal…
The introduction of bias in the design and analysis of studies likely explains a reported reduction of mortality with antacid therapy in patients with idiopathic pulmonary fibrosis (IPF), according to a new Canadian review study. The research, “The effect of anti-acid therapy on survival in idiopathic…
Formaldehyde, a chemical widely used in construction, health, and manufacturing industries, was seen to worsen lung inflammation and fibrosis in a mouse model of pulmonary fibrosis (PF), a Brazilian study reports. In mice lungs, the chemical was found to increase the amount of collagen, a protein responsible for tissue…
A common oral medication for type 2 diabetes called metformin was seen to quickly reverse pulmonary fibrosis in a mouse model of the disease and lessen fibrosis in lung tissue of PF patients, a study reports, adding that similar compounds might have similar benefits. The research, “Metformin reverses…
Galectin Therapeutics was issued a patent for its lead investigative therapy GR-MD-02 for the treatment of pulmonary fibrosis by the U.S. Patent and Trademark Office (USPTO), the company announced. GR-MD-02 is a carbohydrate-based medicine that binds and stops the action of the galectin-3 protein, which is directly involved in multiple…
The Pulmonary Fibrosis Foundation (PFF) has launched its Oxygen Information Line to provide information and resources to help people using supplemental oxygen and their caregivers. Using the line, people can get reliable advice about which oxygen delivery system to use, how to manage flow settings, and how to ensure safety.
Mediaplanet, a content marketing company, recently launched a “Personal Health” campaign that helps to raise awareness of different forms of lung disease, from pulmonary fibrosis and cancer to asthma and chronic obstructive pulmonary disease. According to a press release, the campaign — which covers other chronic diseases…
The Arizona Biomedical Research Commission awarded a $750,000 grant to researchers at University of Arizona (UA) College of Medicine for their innovative, plant-based model system — a “lung” growing on a leaf — to study pulmonary diseases that range from fibrosis to inflammation and infection. The three-year grant was given to Kenneth…
Get regular updates to your inbox.
